Supplementary Figure S3 from The Irreversible FGFR Inhibitor KIN-3248 Overcomes FGFR2 Kinase Domain Mutations

Supplementary Figure S3. Treatment with KIN-3248 is well-tolerated when administered orally at doses up to 15 mg/kg daily. Data are from the CCLP-1 model engineered with the FGFR2-PHGDH fusion (n=8 mice/group) and are presented as mean ± SEM.